Medicare与退伍军人健康管理局治疗的癌症患者临终费用轨迹比较
本研究回顾性分析2010至2014财年VA与Medicare行政数据,纳入36,401例同时参加VA和Medicare的癌症死亡患者,采用三水平广义估计方程评估临终最后一年月度费用轨迹。结果显示三组总费用轨迹显著不同,但视觉检查显示三组临终费用模式相似,均接近死亡时费用急剧上升,主要由住院费用驱动。
要点
- 三组总费用轨迹显著不同,但临终费用模式视觉上相似。
- 住院费用轨迹在Medicare依赖组与VA依赖组间显著不同。
- 门诊和药物费用轨迹在VA依赖组与混合依赖组间显著不同。
核心结论
- 尽管财务激励和组织结构差异显著,VA和Medicare治疗的癌症患者临终费用均呈上升模式,主要由住院费用驱动。
- 两个系统均需改进以确保临终照护质量与推荐实践一致。
研究设计与样本
- 回顾性分析VA和Medicare行政数据,FY 2010至2014。
- 采用三水平广义估计方程评估最后一年月度费用轨迹,患者嵌套于医院转诊区。
- 共纳入36,401例死于癌症且同时参加VA和Medicare的患者。
主要发现
- 三组总费用轨迹在最后一年显著不同。
- 住院费用轨迹在Medicare依赖组与VA依赖组间显著不同,但在VA依赖组与混合依赖组间无差异。
- 门诊和药物费用轨迹在VA依赖组与混合依赖组间显著不同,但在VA依赖组与Medicare依赖组间无差异。
- 视觉检查显示三组临终费用模式相似,接近死亡时费用急剧上升,主要由住院费用驱动。
关键数值与推荐
- 根据最后一年医疗利用将患者分为VA依赖、Medicare依赖或混合依赖。
- 评估总费用、住院费用、门诊费用和药物费用的轨迹。
临床怎么用
- 老年医学科医生应关注癌症临终患者费用上升主要由住院费用驱动,优化临终照护以减少不必要住院。
- 在VA和Medicare两种系统中,均需改进临终照护质量以符合推荐实践。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/OBJECTIVES: To evaluate differences in end-of-life cost trajectories for cancer patients treated through Medicare versus by the Veterans Health Administration (VA). DESIGN: A retrospective analysis of VA and Medicare administrative data from FY 2010 to 2014. We employed three-level generalized estimating equations to evaluate monthly cost trajectories experienced by patients in their last year of life, with patients nested within hospital referral region. SETTING: Care received at VA facilities or by Medicare-reimbursed providers nationwide. PARTICIPANTS: A total of 36,401 patients dying from cancer and dually enrolled in VA and Medicare. MEASUREMENTS: We evaluated trajectories for total, inpatient, outpatient, and drug costs, using the last 12 months of life. Cost trajectories were prioritized as costs are not directly comparable across Medicare and VA. Patients were assigned to be VA-reliant, Medicare-reliant or Mixed-reliant based on their healthcare utilization in the last year of life. RESULTS: All three groups experienced significantly different cost trajectories for total costs in the last year of life. Inpatient cost trajectories were significantly different between Medicare-reliant and VA-reliant patients, but did not differ between VA-reliant and Mixed-reliant patients. Outpatient and drug cost trajectories exhibited the inverse pattern: they were significantly different between VA-reliant and Mixed-reliant patients, but not between VA-reliant and Medicare-reliant patients. However, visual examination of cost trajectories revealed similar cost patterns in the last year of life among all three groups; there was a sharp rise in costs as patients approach death, largely due to inpatient care. CONCLUSION: Despite substantially different financial incentives and organization, VA- and Medicare-treated patients exhibit similar patterns of increasing end-of-life costs, largely driven by inpatient costs. Both systems require improvement to ensure quality of end-of-life care is aligned with recommended practice.
引用
- Gidwani R, Asch SM, Needleman J, et al. End-of-Life Cost Trajectories in Cancer Patients Treated by Medicare versus the Veterans Health Administration. J Am Geriatr Soc. 2020. PMID: 33368171. doi:10.1111/jgs.16941
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。